Mandate

Vinge advises Oncopeptides in connection with a directed share issue

The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncopeptides will raise proceeds of approximately SEK 1,106 million, before issue costs.

The share issue is directed to a number of selected international and Swedish reputable investors and life sciences specialist investors, on the basis of an accelerated bookbuilding process conducted by Carnegie, Cowen, DNB Markets, JP Morgan and Kempen & Co.

Oncopeptides is a clinical development pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company’s shares are admitted to trading on Nasdaq Stockholm.

Vinge’s team has consisted of Dain Hård Nevonen, Linnéa Sellström and Hampus Olsson.

 

Related

Vinge has advised Gränges on the refinancing of its sustainability-linked credit facility

Vinge has advised Gränges AB (publ) (“Gränges”), a global leader in aluminium rolling and recycling in selected niches, on the refinancing of its sustainability-linked credit facility, which supports Gränges’ sustainability plan.
February 10, 2025

Vinge has advised Priveq Fund VII in connection with a sustainability-linked credit facility

Priveq Fund VII has entered into a credit facility agreement with Swedbank AB (publ) which will primarily be used to finance the fund’s investment activities. The credit facility is linked to certain of Priveq’s sustainability targets, which means that the interest rate on the credit facility will be adjusted up or down based on the performance of Priveq Fund VII's portfolio companies.
February 10, 2025

Vinge advised ReCarber in financing round

Vinge has advised ReCarber AB in its SEK 60 million financing round. The investors included Luminar Ventures, Spintop Ventures and Course Corrected.
February 10, 2025